Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2025
Date Filed: September 15, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this Form 6-K serves as a procedural notice rather than a financial results report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this document. The filing incorporates by reference into existing Registration Statements on Form S-8 and Form F-3.
Guidance, Outlook, and Risks
Management Commentary: None provided in this specific filing.
Exhibits: The filing includes Exhibit 99.1, a "Notice Under Section 708A."
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this Form 6-K.
Investor Verification Checklist
- Verify the content of the "Notice Under Section 708A" (Exhibit 99.1) referenced in the filing.
- Review the incorporated Registration Statements (Form S-8 and Form F-3) for updated financial data and operational status.
- Confirm the company's continued status as a development stage enterprise and its cash runway.